Bioventus (BVS) Earnings Date & Reports

Key Takeaways

• Third-quarter 2026 revenue rose 3% to $142.4 million but missed the roughly $149.5 million consensus estimate.
• Adjusted earnings per share (EPS) came in at $0.17, topping analyst expectations and up 13% from $0.15 a year earlier.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $28 million, with the margin expanding 70 basis points to 20%.
• Full-year 2026 revenue guidance was lowered to $590–$595 million, while adjusted EPS guidance of $0.75–$0.79 was reaffirmed.
• Pain Treatments led growth at 6%, while softness in Bone Graft Substitutes (BGS) weighed on Surgical Solutions.
• For more context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Discover AI-driven trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Bioventus Inc. (Nasdaq: BVS) is a global medical device company focused on active healing and musculoskeletal therapies. Its third-quarter 2026 report, released on November 2, 2026 for the period ended September 26, 2026, offered investors an important checkpoint on whether the company's growth drivers—peripheral nerve stimulation (PNS), platelet-rich plasma (PRP), Ultrasonics, and international expansion—could offset headwinds in its bone graft business. The results also landed against the backdrop of an ongoing strategic review, prompted by an unsolicited acquisition proposal and multiple expressions of interest. Because management updated its full-year outlook, this report carries meaningful weight for how analysts and shareholders assess the company's near-term trajectory.

Reported Results

Bioventus reported third-quarter 2026 net sales of $142.4 million, a 3% increase from $138.7 million in the prior-year period but below the roughly $149.5 million consensus estimate. Adjusted earnings per diluted share came in at $0.17, topping analyst expectations and advancing 13% from $0.15 a year earlier. On a GAAP (Generally Accepted Accounting Principles) basis, net income attributable to Bioventus was $6.0 million, or $0.08 per diluted share, compared with $3.2 million, or $0.05 per diluted share, in the year-ago quarter.

Adjusted EBITDA rose to $28 million, with the adjusted EBITDA margin expanding 70 basis points to 20%. By segment, Pain Treatments revenue grew 6% to $71 million, Surgical Solutions rose 1% to $51 million, and Restorative Therapies declined 3% to $21 million. International revenue increased 16% to $18 million. Management attributed the top-line shortfall primarily to weaker-than-expected Bone Graft Substitutes (BGS) within Surgical Solutions.

The company lowered its full-year 2026 net sales guidance to a range of $590 million to $595 million, down from $600 million to $610 million previously, while reaffirming its full-year adjusted EPS outlook of $0.75 to $0.79.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for investors monitoring names like Bioventus and the broader medical device space.

Market Reaction and Investor Sentiment

Shares of Bioventus fell sharply in after-hours trading following the release, with reported declines ranging from roughly 11% to 19% as investors weighed the revenue miss and the reduction to full-year sales guidance against the earnings beat. The stock had risen substantially year-to-date heading into the report, which likely amplified the negative reaction to the softer top line. Sentiment was tempered by management's characterization of the BGS softness as transitory, as well as its decision to reaffirm the full-year adjusted EPS outlook, but the sales shortfall and lower revenue forecast remained the dominant near-term concern.

Forward Outlook and Key Factors to Monitor

Management expects a sequential acceleration in revenue growth in the fourth quarter, citing mid-single-digit growth expectations and early positive trends in October following corrective actions in the BGS business. Investors will be watching whether the bone graft segment stabilizes and whether the company's growth drivers continue to gain traction.

On the growth front, PNS and PRP are progressing, with PRP disposable kit revenue exceeding capital placements for the first time and trial-to-permanent conversion rates running ahead of plan. Ultrasonics delivered strong double-digit growth, and international revenue is projected to grow more than 20% in the fourth quarter. These are key indicators of whether the company can broaden its revenue base beyond its legacy portfolio.

Balance sheet momentum is another area to monitor. Bioventus generated $21 million in cash from operations during the quarter, repaid an additional $19 million of debt, and reduced net debt below $200 million, with management targeting a net leverage ratio below 1.5 times by year-end. Finally, the ongoing strategic alternatives review—initiated by unsolicited acquisition interest—remains an important wildcard that could shape the company's future direction.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations